Estadístiques de The novel oral mTORC1/2 inhibitor TAK-228 reverses trastuzumab resistance in HER2-positive breast cancer models
Visites totals
| views | |
|---|---|
| The novel oral mTORC1/2 inhibitor TAK-228 reverses trastuzumab resistance in HER2-positive breast cancer models | 66 |
Visites totals per mes
| views | |
|---|---|
| January 2025 | 0 |
| February 2025 | 1 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
| June 2025 | 0 |
| July 2025 | 0 |
Visites al fitxer
| views | |
|---|---|
| Sanz_can_nove.pdf(legacy) | 76 |
| Sanz_can_nove.pdf | 69 |
Vistes principals per país
| views | |
|---|---|
| United States | 53 |
| Spain | 6 |
| Poland | 3 |
| Argentina | 1 |
| Belgium | 1 |
| Germany | 1 |
| Romania | 1 |
Visites principals per ciutat
| views | |
|---|---|
| San Ramon | 22 |
| Barcelona | 5 |
| Ashburn | 4 |
| Mountain View | 4 |
| Ann Arbor | 2 |
| Boardman | 2 |
| Dearborn | 2 |
| Menlo Park | 2 |
| Bucharest | 1 |
| Cambridge | 1 |
| Fairfield | 1 |
| Munich | 1 |
| Murcia | 1 |
| Rochester | 1 |
| San Diego | 1 |
| Suipacha | 1 |
| Tustin | 1 |